Physician profile
Rui Lu
NPI 1356308332
$11,847.76
in general payments reported to CMS, 2019-2025
37 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,814 · 2020: $1,156 · 2021: $2,783 · 2022: $1,604 · 2023: $1,042 · 2024: $1,329 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,626.36 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $1,592.42 | 2019-2023 | |
| Lilly USA, LLC | $1,524.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Senseonics, Incorporated | $1,200.00 | 2024-2025 | Eversense |
| Astrazeneca Pharmaceuticals Lp | $703.38 | 2019-2025 | Farxiga |
| Abbvie INC. | $439.16 | 2019-2022 | |
| Mannkind Corporation | $361.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.49 | 2020-2025 | Jardiance |
| Ascensia Diabetes Care US INC. | $314.39 | 2022-2024 | |
| Amgen INC. | $304.89 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $301.06 | 2022-2025 | |
| Abbott Laboratories | $281.42 | 2019-2025 | Freestyle Libre 3, Freestyle Libre Pro |
| Insulet Corporation | $271.89 | 2025 | Omnipod, Omnipod |
| Corcept Therapeutics | $254.95 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $224.71 | 2020-2024 | Gvoke Hypopen, Recorlev |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $157.97 | 2021-2022 | |
| Antares Pharma, INC. | $124.62 | 2022-2024 | Xyosted |
| Medtronic, INC. | $103.56 | 2021-2022 | |
| Amarin Pharma, INC. | $88.72 | 2019-2021 | |
| Dexcom, INC. | $88.43 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $75.45 | 2019 | |
| Beta Bionics, INC. | $69.53 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $53.43 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $45.90 | 2019-2021 | |
| Cequr Corporation | $42.86 | 2024-2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.56 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.00 | 2024 | Crysvita |
| Ibsa Pharma INC. | $25.00 | 2021 | |
| Horizon Therapeutics Plc | $24.90 | 2023 | Tepezza |
| Celgene Corporation | $24.12 | 2025 | Opdivo |
| Esperion Therapeutics, INC. | $22.85 | 2025 | Nexletol |
| Madrigal Pharmaceuticals | $19.49 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $18.50 | 2024 | Veozah |
| Embecta Corp. | $15.45 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Alnylam Pharmaceuticals INC. | $14.83 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.04 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rui Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.